Archean Chemical Industries Ltd

- The company expects volume growth to continue, especially driven by marine chemicals and derivatives businesses. - Bromine sales volumes are targeted to increase to north of 18,000 tons next year, with a medium-term goal of reaching 25,000 tons run rate before further expansion. - Bromine derivatives (Acume) are currently at 30-40% utilization; target is to scale up to 60-70% utilization by FY'27. - SOP plant-scale trials will commence soon, expecting meaningful revenue contributions in the latter half of FY'27. - The Oren Hydrocarbons business's revenue contribution has shifted to FY'27 due to regulatory and operational delays. - Despite near-term operational challenges causing delays, management is confident of scaling up production and ramping up new product portfolios leading to improved EBITDA and profits starting FY'27. - The company anticipates steady earnings growth with improving margins as operational disruptions are resolved and new initiatives contribute.

- Current order backlog for elemental bromine is around 6,500 tons (not derivatives). - This backlog is spread across various geographies and industries with no single dominant factor. - The orders have staggered delivery schedules over a longer period, not meant for immediate dispatch. - The company maintains a balance between short-term and long-term contracts within this orderbook. - Majority of orders are focused on Asian markets, particularly Asia Pacific. - Specific industry details for the order volumes were not provided; the company requested inquiries to be sent to Investor Relations for detailed info. - As volumes ramp up, backlog is expected to be worked through, and ongoing repricing is occurring. - No significant change or shift in order trends currently observed. (Reference: Page 20 Q&A between Rohit Sinha and Rampraveen Swaminathan)

- The company is currently finalizing the funding framework related to the semiconductor project with the Indian Semiconductor Mission. - Discussions are ongoing, and the financial support agreement is expected to be completed soon. - There is no clear end date yet for finalization of this funding. - Once finalized, the company will provide more specific details about timing and impact. - No explicit mention of raising new debt or equity outside this context is provided. - Management emphasized that the semiconductor project funding is an external dependency they are actively working on.

- Archean Chemical Industries is progressing with its semiconductor business initiative (SiCSem), approved under the Indian Semiconductor Mission. Execution is underway on a 25-acre site in Bhubaneshwar with site allotment, groundbreaking, land leveling, and ongoing surveys. The finalization of the fiscal support agreement with the Indian Semiconductor Mission is in progress. - The company is evaluating a flame retardant bromine project; currently in the project evaluation phase with a focus on feasibility and scaling. - Continued investment in developing the go-to-market strategy and finalizing supply partners for semiconductor fab design, EPC, and project execution. - Investment in Offgrid Energy Labs (18.14% acquired), innovating zinc bromide batteries with plans to set up a 10-megawatt-hour demo manufacturing facility in the U.K. - Minor brownfield expansions are planned to increase bromine capacity from current levels to a target of 40,000 tons. These indicate ongoing and future strategic and capital investments in advanced materials, energy storage, and core chemical businesses.

- The company aims to increase elemental bromine production to north of 18,000 tons next year, with a medium-term target to reach a run rate between 18,000 and 25,000 tons. - Plans for brownfield expansion to raise capacity from 25,000 tons towards 40,000 tons, aligned with growth in the derivatives business. - Bromine derivative (Acume) plant utilization targeted to scale up from current 30-40% to around 60-70% during FY 2026-27, supported by expanded product portfolio and accelerated customer acceptance. - Industrial salt volumes are growing steadily with volumes reverting back to over 1 million tons quarterly, supporting stable revenue. - SOP plant scale trials are commencing; meaningful contributions expected in the latter half of FY 2027. - Overall, volume growth is expected to continue driven by captive consumption and stable demand, despite some near-term operational and external challenges.